Trasis Revenue and Competitors
Estimated Revenue & Valuation
- Trasis's estimated annual revenue is currently $15M per year.
- Trasis's estimated revenue per employee is $47,619
Employee Data
- Trasis has 315 Employees.
- Trasis grew their employee count by 23% last year.
Trasis's People
Name | Title | Email/Phone |
---|---|---|
1 | QA Officer | Reveal Email/Phone |
2 | Head Quality and Regulatory | Reveal Email/Phone |
3 | Head Human Resources | Reveal Email/Phone |
4 | Head Chemistry | Reveal Email/Phone |
5 | Head Operations | Reveal Email/Phone |
6 | Procurement & Purchasing Officer | Reveal Email/Phone |
7 | Planning & Administrative Officer | Reveal Email/Phone |
8 | QA & QC officer | Reveal Email/Phone |
9 | Human Resources Officer | Reveal Email/Phone |
10 | Purchasing and Sourcing Officer | Reveal Email/Phone |
Trasis Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 67 | 49% | N/A | N/A |
#2 | N/A | 119 | 19% | N/A | N/A |
#3 | $15M | 315 | 23% | N/A | N/A |
What Is Trasis?
At Trasis our primary focus is allowing the medical community to access new radiolabelled therapeutic and diagnostic substances easier and faster. To this end, we design, manufacture, sell and support high performance synthesizers, dose preparation equipment, their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs. Our proven radiopharmaceutical expertise, coupled with our high end instruments allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization. Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies.
keywords:N/AN/A
Total Funding
315
Number of Employees
$15M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator